Advertisement: Kao Data Centre mid banner
Advertisement: S-Tech mid banner 2
Mid banner advertisement: BDO
Barr Ellison Solicitors – commercial property
Advertisement: HCR mid banner
Advertisement: partnersand mid banner
Advertisement: Simpsons Creative
Advertisement: Mogrify mid banner
Advertisement: EBCam mid banner
Advertisement: Cambridge Network mid banner
Advertisement: Wild Knight Vodka
29 March, 2012 - 12:02 By News Desk

TAP Czech’s into eastern Europe

The CellBase CT system

TAP Biosystems, a Cambridge UK medtech innovator, has won a major new contract in eastern Europe.

TAP says EU funding for new technologies is boosting interest in the region for manufacturing biotech products.

The company, which supplies cell culture systems and consumables for life science applications, is installing a system to automate the ex-vivo expansion of autologous cell therapies at Czech-based firm PrimeCell, one of central and eastern Europe’s largest regenerative medicine companies.

The CellBase CT system at PrimeCell will be used in the Czech company’s new GMP facility at the National Tissue Centre Inc to rapidly scale up its manual cell culture processes in T-flasks.

It will provide a fully-contained aseptic cell expansion area. This will allow scientists to manufacture multiple autologous cell therapies from many individual patients in parallel and will enable the company to supply clients, including regional transplant centres in the Czech Republic, with a range of clean autologous therapies.

Dr Ralph von Strandmann, TAP Biosystems' European sales manager stated: “With EU funding for new technologies, there has been an increasing interest in manufacturing biotechnology products in Central and Eastern Europe.

“This has led progressive companies here to realise that utilising efficient methods of manufacturing cell therapies will provide them with a significant advantage in this competitive sector.

“We are pleased that PrimeCell will be using CellBase CT to automate expansion of their autologous stem cell therapies. It is an excellent, cost-efficient alternative to labour intensive manual cell culture and could help make autologous cell therapies less expensive and more widely accessible to patients in Central and Eastern Europe.”

Add new comment

Newsletter Subscription

Stay informed of the latest news and features